Immunic (IMMU) Announces $400M Oversubscribed Private Placement; Shares Rise

Immunic Pharmaceuticals (IMMU) announced on February 13, 2026, the completion of a $400 million private placement, oversubscribed with strong institutional demand. The proceeds will fund the commercialization of its lead therapy, IMMU-210, with a new commercial agreement signed with a major pharma partner. The company's stock closed at $18.75, up 12.3% on the NASDAQ, reflecting investor confidence in the funding and partnership.